Q-omics provides the consensus-scored IFNWP5 profile across patient tissues and cancer cell-line models. IFNWP5 expression is associated with patient survival in 6 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, IFNWP5 is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, IFNWP5 RNA expression shows 8,975 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight LUAD, KIRC, and COAD as cancer lineages where IFNWP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IFNWP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IFNWP5 survival associations across molecular data types. IFNWP5 RNA expression shows survival associations in the most cancer types (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IFNWP5 RNA expression–survival associations across cancer types. High IFNWP5 expression shows unfavorable associations in LUAD, KIRC, BLCA, PAAD, LGG and KIRP. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LUAD as the clearest survival context for IFNWP5 RNA expression.
This table summarizes IFNWP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for IFNWP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IFNWP5 shows lower tumor expression in KIRC, KICH and KIRP. The KIRC box plot shows higher IFNWP5 RNA expression in normal versus tumor tissue (log2 FC = −0.364, t-test p < 0.001).
This table shows molecular features associated with IFNWP5 in patient tissues and cancer cell lines. In patient samples, IFNWP5 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
